An Oxidized Lipid-Peroxisome Proliferator-Activated Receptor γ-Chemokine Pathway in the Regulation of Macrophage-Vascular Smooth Muscle Cell Adhesion

Trends in Cardiovascular Medicine

Volumn 17, Issue 8, 2007, Pages 269-274

  Barlic, Jana ^a,b   Murphy, Philip M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ATHEROGENESIS; CELL ADHESION; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ARTERIOSCLEROSIS; CELL ADHESION; CHEMOKINE CCL2; CHEMOKINE CX3CL1; CHEMOKINES, CX3C; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PPAR GAMMA; RECEPTORS, CCR2; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 36049036174     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2007.09.004     Document Type: Review

References (69)

1. Aiello R.J., Bourassa P.A., Lindsey S., et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 19 (1999) 1518-1525
2. Akiyama T.E., Sakai S., Lambert G., et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22 (2002) 2607-2619
3. Babaev V.R., Yancey P.G., Ryzhov S.V., et al. Conditional knockout of macrophage PPAR{gamma}increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25 (2005) 1647-1653
4. Barak Y., Nelson M.C., Ong E.S., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4 (1999) 585-595
5. Barlic J., Zhang Y., Foley J.F., and Murphy P.M. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor {gamma}-dependent pathway. Circulation 114 (2006) 807-819
6. Barroso I., Gurnell M., Crowley V.E., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 (1999) 880-883
7. Bazan J.F., Bacon K.B., Hardiman G., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 385 (1997) 640-644
8. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
9. Campia U., Matuskey L.A., and Panza J.A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113 (2006) 867-875
10. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354 (2006) 610-621
11. Charo I.F., and Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ Res 95 (2004) 858-866
12. Combadiere C., Potteaux S., Gao J.L., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107 (2003) 1009-1016
13. Daoudi M., Lavergne E., Garin A., et al. Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1. J Biol Chem 279 (2004) 19649-19657
14. Deeb S.S., Fajas L., Nemoto M., et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20 (1998) 284-287
15. Duan S.Z., Ivashchenko C.Y., Russell M.W., et al. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 97 (2005) 372-379
16. Fong A.M., Robinson L.A., Steeber D.A., et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188 (1998) 1413-1419
17. Garton K.J., Gough P.J., and Blobel C.P. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276 (2001) 37993-38001
18. Geissmann F., Jung S., and Littmann D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 (2003) 71-82
19. Gerrity R.G. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 103 (1981) 181-190
20. Gerrity R.G., Goss J.A., and Soby L. Control of monocyte recruitment by chemotactic factor(s) in lesion-prone areas of swine aorta. Arteriosclerosis 5 (1985) 55-66
21. Ghilardi G., Biondi M.L., Turri O., et al. Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke 35 (2004) 1276-1279
22. Glavind J., and Hartmann S. The occurrence of peroxidized lipids in atheromatous human aortas. Experimentia 7 (1951) 464
23. Gosling J., Slaymaker S., Gu L., et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103 (1999) 773-778
24. Gu L., Okada Y., Clinton S.K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2 (1998) 275-281
25. Guo J., Van Eck M., Twisk J., et al. Transplantation of monocyte CC-chemokine receptor 2-deficient bone marrow into ApoE3-Leiden mice inhibits atherogenesis. Arterioscler Thromb Vasc Biol 23 (2003) 447-453
26. Han K.H., Chang M.K., Boullier A., et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor {gamma}. J Clin Invest 106 (2000) 793-802
27. Harland W.A., Gilbert J.D., and Brooks C.J. Lipids of human atheroma. 8. Oxidised derivatives of cholesteryl linoleate. Biochim Biophys Acta 316 (1973) 378-385
28. He W., Barak Y., Hevener A., et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100 (2003) 15712-15717
29. Hevener A.L., He W., Barak Y., et al. Muscle-specific PPARγ deletion causes insulin resistance. Nat Med 9 (2003) 1491-1497
30. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
31. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
32. Jira W., Spiteller G., Carson W., and Schramm A. Strong increase in hydroxy fatty acids derived from linoleic acid in human low density lipoproteins of atherosclerotic patients. Chem Phys Lipids 91 (1998) 1-11
33. Knouff C., and Auwerx J. Peroxisome proliferator-activated receptor-{gamma} calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25 (2004) 899-918
34. Lehrke M., and Lazar M.A. The many faces of PPARgamma. Cell 123 (2005) 993-999
35. Lei Z.B., Zhang Z., Jing Q., et al. OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. Cardiovasc Res 53 (2002) 524-532
36. Lesnik P., Haskell C.A., and Charo I.F. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 111 (2003) 333-340
37. Li A.C., and Palinski W. Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu Rev Pharmacol Toxicol 46 (2006) 1-39
38. Ludwig A., and Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost 97 (2007) 649-703
39. Masugi J., Tamori Y., Mori H., et al. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 268 (2000) 178-182
40. McDermott D.H., Halcox J.P.J., Schenke W.H., et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 89 (2001) 401-407
41. McDermott D.H., Fong A.M., Yang Q., et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 111 (2003) 1241-1250
42. McDermott D.H., Yang Q., Kathiresan S., et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 112 (2005) 1113-1120
43. Meisner F., Walcher D., Gizard F., et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol 26 (2006) 845-850
44. Miles P.D., Barak Y., He W., et al. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 105 (2000) 287-292
45. Moatti D., Faure S., Fumeron F., et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97 (2001) 925-928
46. Murphy P.M., Baggiolini M., Charo I.F., et al. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52 (2000) 145-176
47. Nelken N.A., Coughlin S.R., Gordon D., and Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88 (1991) 1121-1127
48. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
49. Ortlepp J.R., Vesper K., Mevissen V., et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med 81 (2003) 363-367
50. Odegaard J.I., Ricardo-Gonzales R.R., Goforth M.H., et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 446 (2007) 1116-1121
51. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101 (2000) 235-238
52. Rayner K., Van E.S., Groot P.H., and Reape T.J. Localisation of mRNA for JE/MCP-1 and its receptor CCR2 in atherosclerotic lesions of the ApoE knockout mouse. J Vasc Res 37 (2000) 93-102
53. Ricote M., Huang J., Fajas L., et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 95 (1998) 7614-7619
54. Ricote M., Li A.C., Willson T.M., et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
55. Ridker P.M., Cook N.R., Cheng S., et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23 (2003) 859-863
56. Rios-Vazquez R., Marzoa-Rivas R., Gil-Ortega I., and Kaski J.C. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs 6 (2006) 231-242
57. Ristow M., Muller-Wieland D., Pfeiffer A., et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339 (1998) 953-959
58. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
59. Shu H., Wong B., Zhou G., et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 267 (2000) 345-349
60. Sidhu J.S., Cowan D., and Kaski J.C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42 (2003) 1757-1763
61. Szalai C., Duba J., Prohaszka Z., et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 158 (2001) 233-239
62. Tacke F., Alvarez D., Kaplan T.J., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 117 (2007) 185-194
63. Teupser D., Pavlides S., Tan M., et al. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci U S A 101 (2004) 17795-17800
64. Tontonoz P., Nagy L., Alvarez J.G., et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
65. Verreth W., Ganame J., Mertens A., et al. Peroxisome proliferator-activated receptor-{alpha},{gamma}-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Arterioscler Thromb Vasc Biol 26 (2006) 922-928
66. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 344 (1994) 793-795
67. Weber C., Schober A., and Zernecke A. Chemokines-key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 24 (2004) 1997-2008
68. Wong B.W.C., Wong D., and McManus B.M. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 11 (2002) 332-338
69. Yla-Herttuala S., Lipton B.A., Rosenfeld M.E., et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A 88 (1991) 5252-5256